Prosecution Insights
Last updated: November 04, 2026
Application No. 17/914,612

SELECTIVE GIP RECEPTOR AGONISTS COMPRISING A CHELATING MOIETY FOR IMAGING AND THERAPY PURPOSES

Non-Final OA §101§112
Filed
Sep 26, 2022
Priority
Mar 31, 2020 — EU 20315081.8 +2 more
Examiner
CHERNYSHEV, OLGA N
Art Unit
1675
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Antaros Medical AB
OA Round
1 (Non-Final)
54%
Grant Probability
Moderate
1-2
OA Rounds
0m
Est. Remaining
88%
With Interview

Examiner Intelligence

Grants 54% of resolved cases
54%
Career Allowance Rate
525 granted / 963 resolved
-5.5% vs TC avg
Strong +34% interview lift
Without
With
+34.0%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
64 currently pending
Career history
1017
Total Applications
across all art units

Statute-Specific Performance

§101
15.7%
-24.3% vs TC avg
§103
8.4%
-31.6% vs TC avg
§102
11.6%
-28.4% vs TC avg
§112
47.2%
+7.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 963 resolved cases

Office Action

§101 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Formal matters 1. The Art Unit location of your application in the USPTO has changed. To aid in correlating any papers for this application, all further correspondence regarding this application should be directed to Art Unit 1675. Election/Restrictions 2. Applicant's election with traverse of “the species wherein X24 is Glu, X31 is Lys (DOTA), and R1 is NH2” in the reply filed on September 24, 2026 is acknowledged. The traversal is on the ground(s) that “the instant claims define a narrow genus of peptidic compounds sharing a common structural feature defining a contribution over the prior art,” p. 3 of the Response. This is found persuasive, and all species/claims will be examined. The election of species requirement is thereby withdrawn. 3. Claims 1-15 are under examination. Sequence compliance 4. This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821 (a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. § 1.821 through 1.825. Specifically, no sequence identification has been provided for the amino acid sequence presented in claim 1, at p. 6 and at p. 41, formula (I) compound. In case this sequence is new, Applicant needs to provide a substitute computer readable form (CRF) copy of a “Sequence Listing” which includes all of the sequences that are present in the instant application and encompassed by these rules, a substitute paper copy of that “Sequence Listing”, an amendment directing the entry of that paper copy into the specification, and a statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. § 1.821 (e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d). The instant specification will also need to be amended so that it complies with 37 C.F.R. § 1.821(d) which requires a reference to a particular sequence identifier (SEQ ID NO: ) be made in the specification and claims wherever a reference is made to that sequence. See MPEP 2422.04. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. 5. Claims 1-15 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. 6. Regarding claims 1 and 2, the phrase "may be" renders the claim(s) indefinite because the claim(s) include(s) elements not actually disclosed (those encompassed by "may be," such as a possibility), or subjective (those encompassed by "may be," such as by someone’s permission), thereby rendering the scope of the claim(s) unascertainable. 7. Claims 9-14 provide for the use of a compound of formula (I) but, since the claims do not set forth any steps involved in the method/process, it is unclear what method/process applicant is intending to encompass. A claim is indefinite where it merely recites a use without any active, positive steps delimiting how this use is actually practiced. 8. Claims 3-8 and 15 are indefinite for being dependent from indefinite claim(s). Claim Rejections - 35 USC § 101 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. 9. Claims 9-14 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter. The claim(s) does/do not fall within at least one of the four categories of patent eligible subject matter because the claimed recitation of a use, without setting forth any steps involved in the process, results in an improper definition of a process, i.e., results in a claim which is not a proper process claim under 35 U.S.C 101. See for example Ex parte Dunki, 153 USPQ 678 (Bd. App. 1967) and Clinical Products, Ltd. v. Brenner, 255 F. Supp. 131, 149 USPQ 475 (D.D.C. 1966). Conclusion 10. No claim is allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to OLGA N CHERNYSHEV whose telephone number is (571)272-0870. The examiner can normally be reached 9AM to 5:30PM, Monday to Friday. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey Stucker can be reached at (571)272-0911. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /OLGA N CHERNYSHEV/Primary Examiner, Art Unit 1675 October 27, 2026
Read full office action

Prosecution Timeline

Sep 26, 2022
Application Filed
Oct 29, 2026
Non-Final Rejection mailed — §101, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12775008
BIOMARKERS FOR THE PREDICTION AND IDENTIFICATION OF PARKINSON'S DISEASE
4y 5m to grant Granted Oct 27, 2026
Patent 12774321
Anti-Alpha-Synuclein Monoclonal Antibodies, and Methods Using Same
4y 5m to grant Granted Oct 27, 2026
Patent 12775004
METHODS OF THERAPEUTIC PROGNOSTICATION
4y 2m to grant Granted Oct 27, 2026
Patent 12716893
MATERIALS AND METHODS FOR DETECTING AND TREATING AUTOIMMUNE MOVEMENT DISORDERS
4y 10m to grant Granted Aug 25, 2026
Patent 12710431
DIAGNOSTIC FOR CHILDHOOD RISK OF AUTISM SPECTRUM DISORDER
4y 10m to grant Granted Aug 18, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
54%
Grant Probability
88%
With Interview (+34.0%)
2y 11m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 963 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month